Tag: NULIBRY
Sentynl Therapeutics gets UK MHRA approval for its drug ‘NULIBRY’ to...
NULIBRY® is the first and only treatment in the United Kingdom (UK) for patients with Molybdenum Cofactor Deficiency (MoCD) Type A. MoCD Type A is an ultra-rare, life- threatening genetic disorder
BridgeBio & Sentynl Therapeutics get EU nod for NULIBRY, a therapy...
MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years
US subsidiary of Zydus Lifesciences buys BridgeBio Pharma’s NULIBRY
NULIBRY is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder